Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

Shahrzad Jalali, Tammy Price-Troska, Cole Bothun, Jose (J.C.) Villasboas Bisneto, Hyo Jin Kim, Zhi Zhang Yang, Anne J Novak, Haidong M Dong, Stephen Maxted Ansell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed–Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. We show that HL patients have significantly higher serum levels of soluble PD-1 than healthy controls, and find that both membrane-bound and soluble forms of PD-1 are able to induce PD-L1 reverse signaling in HL cell lines. PD-L1 signaling, which is associated with activation of the MAPK pathway and increased mitochondrial oxygen consumption, is reversed by PD-1 blockade. In summary, our data identify inhibition of reverse signaling through PD-L1 as an additional mechanism that accounts for clinical responses to PD-1 blockade in cHL.

Original languageEnglish (US)
Article number22
JournalBlood cancer journal
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Hodgkin Disease
Cell Survival
Growth
Ligands
Cell Line
Blocking Antibodies
Oxygen Consumption
Disease Progression
Monoclonal Antibodies
Cell Proliferation
Apoptosis
Membranes
Survival
Serum

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma. / Jalali, Shahrzad; Price-Troska, Tammy; Bothun, Cole; Villasboas Bisneto, Jose (J.C.); Kim, Hyo Jin; Yang, Zhi Zhang; Novak, Anne J; Dong, Haidong M; Ansell, Stephen Maxted.

In: Blood cancer journal, Vol. 9, No. 3, 22, 01.03.2019.

Research output: Contribution to journalArticle

@article{4920971c58474f4a9f110edf2a27bd14,
title = "Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma",
abstract = "Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed–Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. We show that HL patients have significantly higher serum levels of soluble PD-1 than healthy controls, and find that both membrane-bound and soluble forms of PD-1 are able to induce PD-L1 reverse signaling in HL cell lines. PD-L1 signaling, which is associated with activation of the MAPK pathway and increased mitochondrial oxygen consumption, is reversed by PD-1 blockade. In summary, our data identify inhibition of reverse signaling through PD-L1 as an additional mechanism that accounts for clinical responses to PD-1 blockade in cHL.",
author = "Shahrzad Jalali and Tammy Price-Troska and Cole Bothun and {Villasboas Bisneto}, {Jose (J.C.)} and Kim, {Hyo Jin} and Yang, {Zhi Zhang} and Novak, {Anne J} and Dong, {Haidong M} and Ansell, {Stephen Maxted}",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41408-019-0185-9",
language = "English (US)",
volume = "9",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma

AU - Jalali, Shahrzad

AU - Price-Troska, Tammy

AU - Bothun, Cole

AU - Villasboas Bisneto, Jose (J.C.)

AU - Kim, Hyo Jin

AU - Yang, Zhi Zhang

AU - Novak, Anne J

AU - Dong, Haidong M

AU - Ansell, Stephen Maxted

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed–Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. We show that HL patients have significantly higher serum levels of soluble PD-1 than healthy controls, and find that both membrane-bound and soluble forms of PD-1 are able to induce PD-L1 reverse signaling in HL cell lines. PD-L1 signaling, which is associated with activation of the MAPK pathway and increased mitochondrial oxygen consumption, is reversed by PD-1 blockade. In summary, our data identify inhibition of reverse signaling through PD-L1 as an additional mechanism that accounts for clinical responses to PD-1 blockade in cHL.

AB - Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates in refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression in HL, we hypothesized that reverse signaling through PD-1 ligands may be a potential mechanism contributing to the growth and survival of Hodgkin Reed–Sternberg (HRS) cells in cHL. Our data show that engagement of PD-L1 using an agonistic monoclonal antibody increases cell survival and proliferation and reduces apoptosis in HL cell lines. We show that HL patients have significantly higher serum levels of soluble PD-1 than healthy controls, and find that both membrane-bound and soluble forms of PD-1 are able to induce PD-L1 reverse signaling in HL cell lines. PD-L1 signaling, which is associated with activation of the MAPK pathway and increased mitochondrial oxygen consumption, is reversed by PD-1 blockade. In summary, our data identify inhibition of reverse signaling through PD-L1 as an additional mechanism that accounts for clinical responses to PD-1 blockade in cHL.

UR - http://www.scopus.com/inward/record.url?scp=85061832661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061832661&partnerID=8YFLogxK

U2 - 10.1038/s41408-019-0185-9

DO - 10.1038/s41408-019-0185-9

M3 - Article

C2 - 30783096

AN - SCOPUS:85061832661

VL - 9

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 3

M1 - 22

ER -